# A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

> **NCT07213960** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 270 (estimated)

## Conditions studied

- FSGS

## Interventions

- **DRUG:** APL2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07213960
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2029-10
- **Final completion:** 2029-12
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213960, "A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07213960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*